Merck faces critical Keytruda patent cliff
Merck's intense dependency on blockbuster Keytruda creates significant revenue risk ahead of its 2028 patent expiration.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.